Please login to the form below

Not currently logged in
Email:
Password:

Israel

This page shows the latest Israel news and features for those working in and with pharma, biotech and healthcare.

Sanofi, Regeneron's Libtayo shows marked reduction in risk of death in cervical cancer patients

Sanofi, Regeneron's Libtayo shows marked reduction in risk of death in cervical cancer patients

Recurrent or metastatic cervical cancer is notoriously difficult to treat and has no approved standard of care after first-line chemotherapy," said Israel Lowy, senior vice president, translational and clinical sciences,

Latest news

More from news
Approximately 3 fully matching, plus 125 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 14 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 13 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 6 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
COUCH Health

We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...

Latest intelligence

Sharing patient stories for World Pulmonary Hypertension Day
For World Pulmonary Hypertension Day and we’re here to help raise awareness of pulmonary hypertension (PH) - a frequently under and misdiagnosed condition. Created in collaboration with the PH patient...
How nature can help you manage the pressures of agency life
Paul Hutchings, founder of fox&cat, outlines how nature can help you can boost staff wellbeing in your agency this Mental Health Awareness Week...
How can we strike the right balance between familiarity and innovation when it comes to data presentation?
Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...